Where does HKPD stock trade?

Cellyan Biotechnology Co. Ltd (HKPD) is listed on NASDAQ.

What sector and industry is HKPD in?

Cellyan Biotechnology Co. Ltd operates in the Health Care sector, Other Pharmaceuticals industry.

When did Cellyan Biotechnology Co. Ltd go public?

Cellyan Biotechnology Co. Ltd (HKPD) completed its IPO in 2025.

What companies are similar to HKPD?

Notable peers in the same industry include MCK (McKesson Corporation), COR (Cencora Inc.), CAH (Cardinal Health Inc.), ABC (AmerisourceBergen Corporation), CVET (Covetrus Inc.). Compare HKPD side-by-side with any of them on Quantisnow.

How can I track HKPD on Quantisnow?

Quantisnow aggregates Cellyan Biotechnology Co. Ltd's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HKPD to receive live email and push alerts on every new disclosure.

HKPD

NASDAQ

Cellyan Biotechnology Co. Ltd

SectorHealth CareIndustryOther PharmaceuticalsIPO2025

$0.48-0.03 (-5.73%)

News23/Ratings0

News · 26 weeks13+100%

2025-12-142026-06-07

Mix890d

SEC Filings4(50%)
Insider4(50%)

Latest news

23 items

2hINSIDER
SEC Form 3 filed by new insider Liu Shu
3 - Cellyan Biotechnology Co., Ltd (0002007702) (Issuer)
2hINSIDER
SEC Form 3 filed by new insider Zhou Mike Yao
3 - Cellyan Biotechnology Co., Ltd (0002007702) (Issuer)
2hINSIDER
SEC Form 3 filed by new insider Wu Jingyan
3 - Cellyan Biotechnology Co., Ltd (0002007702) (Issuer)
2hINSIDER
SEC Form 3 filed by new insider Liang Chenyu Andy
3 - Cellyan Biotechnology Co., Ltd (0002007702) (Issuer)
60dSEC
SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
EFFECT - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)
73dSEC
SEC Form F-1 filed by Cellyan Biotechnology Co. Ltd
F-1 - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)
73dSEC
SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
6-K - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)
82dSEC
SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
6-K - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)
142dSEC
SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
6-K - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)
142dPR
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) (the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the "Notification Letter") dated January 12, 2026 from Nasdaq's Listing Qualifications Department indicating that the closing bid price of the Company's class A ordinary shares of par value of US$0.001 each was below the minimum requirement of US$1.00 per share for 30 consecutive business days from November 26, 2025 through January 9, 2026, and the Company was therefore currently not in compliance with the min
159dSEC
SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
6-K - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)
172dSEC
SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)
172dPR
Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders
HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals: Proposal No. 1: The re-election of five directors, Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, Dr. Kam Leung Chan, each to serve until the 2026 Annual Meeting of Stockholders; Proposal No. 2: The ratific
196dSEC
SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)
207dSEC
SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)
244dSEC
SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)
270dSEC
SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)
298dSEC
SEC Form 20-F filed by Hong Kong Pharma Digital Technology Holdings Limited
20-F - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)
312dSEC
SEC Form NT 20-F filed by Hong Kong Pharma Digital Technology Holdings Limited
NT 20-F - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)
437dSEC
SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)
437dPR
Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024
HONG KONG, March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced its unaudited financial results for the six months ended September 30, 2024. Financial Highlights for the Six Months Ended September 30, 2024: Net Revenues: The Company reported net revenues of $11,091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023.Revenue Breakdown:Six Months endedSeptember 30,2024 Six Months endedSeptember 30,2023 Supply chain services $ 6,329,678 $ 4,646,951 Procurement an
506dSEC
SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
6-K - Hong Kong Pharma Digital Technology Holdings Ltd (0002007702) (Filer)
508dPR
Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company") (NASDAQ:HKPD), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced the closing of its initial public offering (the "Offering") of an aggregate of 1,403,685 ordinary shares, par value $0.001 per share (the "Ordinary Shares") at a public offering price of US$4.00 per share of which 1,000,000 Ordinary Shares were offered by the Company, and 403,685 Ordinary Shares were offered by certain selling shareholders of the Company. Hong Kong Pharma did not receive any proceeds from the sal

HKPD FAQ

5 questions

Where does HKPD stock trade?
Cellyan Biotechnology Co. Ltd (HKPD) is listed on NASDAQ.
What sector and industry is HKPD in?
Cellyan Biotechnology Co. Ltd operates in the Health Care sector, Other Pharmaceuticals industry.
When did Cellyan Biotechnology Co. Ltd go public?
Cellyan Biotechnology Co. Ltd (HKPD) completed its IPO in 2025.
What companies are similar to HKPD?
Notable peers in the same industry include MCK (McKesson Corporation), COR (Cencora Inc.), CAH (Cardinal Health Inc.), ABC (AmerisourceBergen Corporation), CVET (Covetrus Inc.). Compare HKPD side-by-side with any of them on Quantisnow.
How can I track HKPD on Quantisnow?
Quantisnow aggregates Cellyan Biotechnology Co. Ltd's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HKPD to receive live email and push alerts on every new disclosure.